Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus in Recurrent Vulvovaginal Candidiasis
NCT04699240Phase 4Completed
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in recurrent vulvovaginal candidiasis (RVVC), sponsored by Peking University Shenzhen Hospital. Primary endpoint: Cure rate of RVVC at 6 months. Started Jul 2020; status: completed.
02
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on NCT04699240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699240.